Posted by Michael Wonder on 06 Mar 2016
U.S. FDA approves CSL Behring’s Idevlion -- the first and only haemophilia B therapy with up to 14-day dosing intervals
4 March 2016 - Idelvion is indicated in children and adults with haemophilia B for routine prophylaxis to prevent or reduce the frequency of bleeding episodes; on-demand control and prevention of bleeding episodes; and the perioperative management of bleeding (around the time of surgery).
For more details, go to: http://www.cslbehring.com/newsroom/idelvion-for-hemophilia-b-receives-fda-approval
